THC TENET HEALTHCARE CORP
Services-General Medical & Surgical Hospitals, NEC · NYSE · SEC CIK 70318 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.2%
TTM net income YoY114.1%
TTM EPS YoY133.1%
Revenue 3-yr CAGR3.2%
Net income 3-yr CAGR83.5%
Margins
Gross margin—
Operating margin24.4%
Net margin13.1%
FCF margin15.0%
EBITDA margin28.4%
Returns
ROE61.3%
ROA9.5%
ROIC (approx.)28.2%
Asset turnover0.73x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity2.43x
Current ratio1.58x
Interest coverage6.61x
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue4.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $21.31B | $20.68B |
| Operating income | $3.51B | $5.96B |
| Interest expense | $821.00M | $826.00M |
| Pretax income | $2.80B | $5.25B |
| Income tax | $433.00M | $1.18B |
| Net income | $1.41B | $3.20B |
| EBITDA | $4.37B | $6.77B |
| EPS (basic) | 15.61 | 33.02 |
| EPS (diluted) | 15.49 | 32.70 |
| Weighted avg. shares (diluted) | 90.83M | 97.88M |
| Balance sheet | ||
| Cash & equivalents | $2.88B | $3.02B |
| Receivables | $2.56B | $2.54B |
| Inventory | $348.00M | $346.00M |
| Current assets | $7.85B | $7.68B |
| PP&E, net | $6.32B | $6.05B |
| Goodwill | $11.20B | $10.69B |
| Intangibles | $1.35B | $1.40B |
| Total assets | $29.68B | $28.94B |
| Current liabilities | $4.46B | $4.31B |
| Short-term debt | $79.00M | $92.00M |
| Long-term debt | $13.09B | $13.08B |
| Total debt | $13.17B | $13.17B |
| Total liabilities | $20.70B | $20.39B |
| Shareholders' equity | $4.22B | $4.17B |
| Net debt | $10.29B | $10.15B |
| Cash flow statement | ||
| Operating cash flow | $3.54B | $2.05B |
| Capital expenditure | $1.01B | $931.00M |
| Free cash flow | $2.53B | $1.12B |
| Investing cash flow | -$1.27B | $3.43B |
| Financing cash flow | -$2.40B | -$3.69B |
| Depreciation & amortization | $863.00M | $818.00M |
| Stock-based compensation | $104.00M | $67.00M |
| Share buybacks | $1.39B | $672.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.